Genmab Logo

Genmab

Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.

GMAB | CO

Overview

Corporate Details

ISIN(s):
DK0010272202 (+2 more)
LEI:
529900MTJPDPE4MHJ122
Country:
Denmark
Address:
Carl Jacobsens Vej 30, 2500 Valby
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genmab is an international biotechnology company focused on creating and developing differentiated antibody therapeutics for the treatment of cancer and other serious diseases. The company leverages its proprietary antibody science and pioneering technology platforms to innovate next-generation treatments. Genmab's core activities involve the discovery, development, and commercialization of antibody-based products, often in collaboration with strategic partners. Its purpose is to improve the lives of patients by harnessing the power of antibodies to transform medical care.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-19 18:55
Regulatory News Service
English 206.6 KB
2025-11-19 18:55
Director's Dealing
English 7.0 KB
2025-11-18 20:58
Share Issue/Capital Change
English 176.0 KB
2025-11-18 20:58
Share Issue/Capital Change
English 7.8 KB
2025-11-18 17:30
Regulatory News Service
English 244.6 KB
2025-11-18 17:30
Regulatory News Service
English 27.2 KB
2025-10-14 12:23
Earnings Release
English 216.5 KB
2025-10-14 12:23
Earnings Release
English 7.7 KB
2025-09-29 07:08
M&A Activity
English 25.9 KB
2025-09-29 07:08
M&A Activity
English 234.3 KB
2025-09-23 15:18
Major Shareholding Notification
English 175.3 KB
2025-09-23 15:18
Major Shareholding Notification
English 7.2 KB
2025-09-23 15:18
Major Shareholding Notification
English 2.9 MB
2025-09-09 20:57
Director's Dealing
English 7.1 KB
2025-09-09 20:57
Director's Dealing
English 202.5 KB

Automate Your Workflow. Get a real-time feed of all Genmab filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genmab

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genmab via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BIOHARVEST SCIENCES INC. Logo
Biotech platform that grows plant cells to produce active compounds for human wellness products.
United States of America
BHST
Biohaven Ltd. Logo
Clinical-stage biopharma developing drugs for neuroscience, immunology, and oncology.
United States of America
BHVN
BioInfra Co.,Ltd. Logo
Offers cancer screening blood tests and provides CRO services to the pharmaceutical industry.
South Korea
199730
BioInfra Life Science Inc. Logo
Biotech specializing in oncology diagnostics and R&D for cancer gene treatments.
South Korea
266470
BioInvent International Logo
Develops first-in-class immuno-modulatory antibodies for cancer therapy.
Sweden
BINV
BioLineRx Ltd. Logo
Biopharma firm developing and commercializing therapies for cancer and rare diseases.
Israel
BLRX
BIOMARIN PHARMACEUTICAL INC Logo
Develops and commercializes therapies for rare, life-threatening genetic diseases.
United States of America
BMRN
BioMaxima S.A. Logo
Manufacturer of IVD solutions including tests, reagents, and equipment for medical labs.
Poland
BMX
Biomea Fusion, Inc. Logo
Develops oral small molecules for metabolic diseases like diabetes and for specific cancers.
United States of America
BMEA
BIOMERICA INC Logo
Develops diagnostic tests for GI, inflammatory diseases, and diabetes for lab and at-home use.
United States of America
BMRA

Talk to a Data Expert

Have a question? We'll get back to you promptly.